Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Mendizabal

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Annals of Hepatology|April 26, 2023
Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCCFederico Piñero, Margarita Anders, Carla Bermudez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 16, 2024
Development and external validation of a model to predict multidrug-resistant bacterial infections in patients with cirrhosisSebastián Marciano, Salvatore Piano, Virendra Singh, et al.
Journal of Medical Virology|April 4, 2017
Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin AmericaManuel Mendizabal, Leila Haddad, Patricia E Gallardo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 18, 2025
Relink Programmes: Impact of Reengagement on Linkage to Care Across 82 006 People With Hepatitis CMaria Buti, Joost P H Drenth, Manuel Mendizabal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 14, 2019
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinomaFederico Piñero, Manuel Mendizabal, Ezequiel Ridruejo, et al.
Journal of Medical Virology|August 5, 2020
Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohortEzequiel Ridruejo, Federico Piñero, Manuel Mendizabal, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 6, 2020
Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant RecurrenceFederico Piñero, Ilka Boin, Aline Chagas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 2, 2020
Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral AgentsManuel Mendizabal, Federico Piñero, Ezequiel Ridruejo, et al.
Annals of Hepatology|October 10, 2025
Prospective surveillance reveals high rates of antimicrobial resistance in urinary tract infections among patients with cirrhosisCarolina Vazquez, Gonzalo Gómez Perdiguero, Esteban González Ballerga, et al.
Annals of Hepatology|March 8, 2025
Latin American association for the study of the liver (ALEH) guidance on postoperative care after liver transplantationLiana Codes, Rodrigo Zapata, Manuel Mendizabal, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Annals of Hepatology|April 26, 2023
Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCCFederico Piñero, Margarita Anders, Carla Bermudez, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 16, 2024
Development and external validation of a model to predict multidrug-resistant bacterial infections in patients with cirrhosisSebastián Marciano, Salvatore Piano, Virendra Singh, et al.
Journal of Medical Virology|April 4, 2017
Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin AmericaManuel Mendizabal, Leila Haddad, Patricia E Gallardo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 18, 2025
Relink Programmes: Impact of Reengagement on Linkage to Care Across 82 006 People With Hepatitis CMaria Buti, Joost P H Drenth, Manuel Mendizabal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 14, 2019
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinomaFederico Piñero, Manuel Mendizabal, Ezequiel Ridruejo, et al.
Journal of Medical Virology|August 5, 2020
Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohortEzequiel Ridruejo, Federico Piñero, Manuel Mendizabal, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 6, 2020
Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant RecurrenceFederico Piñero, Ilka Boin, Aline Chagas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 2, 2020
Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral AgentsManuel Mendizabal, Federico Piñero, Ezequiel Ridruejo, et al.
Annals of Hepatology|October 10, 2025
Prospective surveillance reveals high rates of antimicrobial resistance in urinary tract infections among patients with cirrhosisCarolina Vazquez, Gonzalo Gómez Perdiguero, Esteban González Ballerga, et al.
Annals of Hepatology|March 8, 2025
Latin American association for the study of the liver (ALEH) guidance on postoperative care after liver transplantationLiana Codes, Rodrigo Zapata, Manuel Mendizabal, et al.
Pageof 9